Biarylmethoxy Nicotinamides As Novel and Specific Inhibitors of Mycobacterium tuberculosis
摘要:
A whole cell based screening effort on a focused library from corporate collection resulted in the identification of biarylmethoxy nicotinamides as novel inhibitors of M. tuberculosis (Mtu) H37Rv. The series exhibited tangible structure activity relationships, and during hit to lead exploration, a cellular potency of 100 nM was achieved, which is an improvement of >200-fold from the starting point. The series is very specific to Mtu and noncytotoxic up to 250 mu M as measured in the mammalian cell line THP-1 based cytotoxicity assay. This compound class retains its potency on several drug sensitive and single drug resistant clinical isolates, which indicate that the compounds could be acting through a novel mode of action.
[EN] ALKYNYL ALCOHOLS AND METHODS OF USE<br/>[FR] ALCOOLS D'ALCYNYLE ET LEURS PROCÉDÉS D'UTILISATION
申请人:HOFFMANN LA ROCHE
公开号:WO2016135163A1
公开(公告)日:2016-09-01
The invention relates to compounds of formula (I), wherein Q, A1-A8, R4 and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
本发明涉及一种新型的杂环吡咯化合物,其作为蛋白激酶B活性抑制剂以及治疗癌症和关节炎的用途。
WO2008/57336
申请人:——
公开号:——
公开(公告)日:——
WO2021032938A5
申请人:——
公开号:WO2021032938A5
公开(公告)日:2023-02-20
Biarylmethoxy Nicotinamides As Novel and Specific Inhibitors of <i>Mycobacterium tuberculosis</i>
作者:Chaitanya Kumar Kedari、Nilanjana Roy Choudhury、Sreevalli Sharma、Parvinder Kaur、Supreeth Guptha、Manoranjan Panda、Kakoli Mukerjee、Vasanthi Ramachandran、Balachandra Bandodkar、Sreekanth Ramachandran、Subramanyam J. Tantry
DOI:10.1021/ml4004815
日期:2014.5.8
A whole cell based screening effort on a focused library from corporate collection resulted in the identification of biarylmethoxy nicotinamides as novel inhibitors of M. tuberculosis (Mtu) H37Rv. The series exhibited tangible structure activity relationships, and during hit to lead exploration, a cellular potency of 100 nM was achieved, which is an improvement of >200-fold from the starting point. The series is very specific to Mtu and noncytotoxic up to 250 mu M as measured in the mammalian cell line THP-1 based cytotoxicity assay. This compound class retains its potency on several drug sensitive and single drug resistant clinical isolates, which indicate that the compounds could be acting through a novel mode of action.